Vectura obtains E2.5 million milestone payment
VR315 is being developed as a generic product delivered with Vectura’s GyroHaler dry powder inhaler delivery device. Vectura licensed the European rights for VR315 to Sandoz, the generics
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.